tbuckley/cabot-search huggingface dataset:
Optimising the efficacy of gait retraining
Authors: Irene Davis
Journal: British Journal of Sports Medicine (2017)

A recent randomised control trial compared the effects of three rehabilitation programmes for patellofemoral pain: education, education and exercises and education and gait retraining.1 I was excited to read this, as I consider gait retraining an important component of patellofemoral pain treatment. Physical therapists are movement experts and in the best position to address faulty movement patterns. Many running-related injuries, especially those more chronic and requiring medical attention, are associated with faulty running mechanics.2 Muscle strengthening alone may not address faulty mechanics.3 While muscle strength is important and can be considered the ‘hardware’ of movementit is the motor pattern, or the ‘software’, that dictates the movement quality. When movement patterns become habitual, altering them during high demand, functional activities such as running takes time and practice and can be challenging.

The goal of gait retraining is to adopt and retain a new motor pattern. Research suggests that this requires an acquisition phase , where extrinsic feedback is provided on a predetermined schedule so that the learner can associated the feedback with their proprioceptive input.4 This is followed by …
SAT0275 Comparison of clinical and serological differences according to the autoantibody cluster in women with systemic lupus erythematosus: results from the korean lupus network (KORNET) registry
Authors: D-J Park, J-H Kang, J-E Kim, K-E Lee, S-S Lee
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> Individual autoantibodies are associated with the clinical features in patients with systemic lupus erythematosus (SLE). However, few studies have investigated differences in disease presentation based on autoantibody profiles in Asian patients with SLE. This study evaluated autoantibody clusters and compared the clinical and serological presentation and clinical outcome in Korean SLE patients. <h3>Methods</h3> The Korean Lupus Network (KORNET) is a nationwide multicenter, hospital-based registry, set up to prospectively assess outcomes in Korean SLE patients. Of the 505 SLE patients enrolled in the KORNET registry from July 2014 to November 2015, the study group comprised 339 consecutive female SLE patients. Seven autoantibodies (anti-dsDNA, anti-Sm, anti-RNP, anti-Ro, anti-La, lupus anticoagulant (LAC), and anti-cardiolipin antibody [aCL]) were selected for cluster analysis using the K-means cluster analysis procedure. <h3>Results</h3> Three distinct autoantibody clusters were identified: cluster 1, anti-dsDNA and anti-Ro; cluster 2, anti-RNP; and cluster 3, anti-RNP, anti-Ro, and anti-La. Compared with patients in clusters 2 (n=99) and 3 (n=85), patients in cluster 1 (n=155) had a shorter symptom duration before SLE diagnosis and higher incidence of biopsy-proven lupus nephritis. Patients in cluster 3 had a higher incidence of discoid rash, central nervous system involvement, lupus pancreatitis, pulmonary arterial hypertension, Raynaud9s phenomenon, and premature gonadal failure. In addition, patients in cluster 3 had the lowest proportion of mean prednisolone &gt;7.5 mg/day in the medication history. <h3>Conclusions</h3> Autoantibody clusters were associated with the clinical features in women with SLE. Clustering autoantibodies could be a valuable approach for differentiating between various clinical subsets of SLE, and may help to guide prediction of the subsequent clinical course and organ damage in these patients. <h3>Disclosure of Interest</h3> None declared
Nonoperative Treatment of Appendicitis—Reply
Authors: Monica E. Lopez, David E. Wesson
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Authors: Elodie M Kuntz, Pablo Baquero, Alison M Michie, Karen Dunn, Saverio Tardito, Tessa L Holyoake, G Vignir Helgason, Eyal Gottlieb
Journal: Nature Medicine (2017)
The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex‐biased autoimmunity
Authors: Heekyong R. Bae, Deborah L. Hodge, Guo‐Xiang Yang, Patrick S.C. Leung, Sathi Babu Chodisetti, Julio C. Valencia, Michael Sanford, John M. Fenimore, Ziaur S.M. Rahman, Koichi Tsuneyama, Gary L. Norman, M. Eric Gershwin, Howard A. Young
Journal: Hepatology (2017)

We have reported on a murine model of autoimmune cholangitis, generated by altering the AU-rich element (ARE) by deletion of the interferon gamma (IFN-γ) 3' untranslated region (coined ARE-Del-/- ), that has striking similarities to human primary biliary cholangitis (PBC) with female predominance. Previously, we suggested that the sex bias of autoimmune cholangitis was secondary to intense and sustained type I and II IFN signaling. Based on this thesis, and to define the mechanisms that lead to portal inflammation, we specifically addressed the hypothesis that type I IFNs are the driver of this disease. To accomplish these goals, we crossed ARE-Del-/- mice with IFN type I receptor alpha chain (Ifnar1) knockout mice. We report herein that loss of type I IFN receptor signaling in the double construct of ARE-Del-/- Ifnar1-/- mice dramatically reduces liver pathology and abrogated sex bias. More importantly, female ARE-Del-/- mice have an increased number of germinal center (GC) B cells as well as abnormal follicular formation, sites which have been implicated in loss of tolerance. Deletion of type I IFN signaling in ARE-Del-/- Ifnar1-/- mice corrects these GC abnormalities, including abnormal follicular structure.Our data implicate type I IFN signaling as a necessary component of the sex bias of this murine model of autoimmune cholangitis. Importantly these data suggest that drugs that target the type I IFN signaling pathway would have potential benefit in the earlier stages of PBC. (Hepatology 2018;67:1408-1419).
Dexamethasone-loaded Polymeric Nanoconstructs for Monitoring and Treating Inflammatory Bowel Disease
Authors: Aeju Lee, Claudia De Mei, Miguel Fereira, Roberto Marotta, Hong Yeol Yoon, Kwangmeyung Kim, Ick Chan Kwon, Paolo Decuzzi
Journal: Theranostics (2017)

Corticosteroids, such as dexamethasone (DEX), are the mainstays for the treatment of moderate to severe inflammatory bowel disease (IBD).However, their relatively poor bioavailability and lack of specificity is often the origin of short and long-term adverse effects.Here, spherical polymeric nanoconstructs (SPNs) encapsulating dexamethasone are proposed for the systemic treatment of IBD.In a mouse model of colitis, the accumulation of SPNs within the inflamed intestine is firstly assessed using near infra-red fluorescent (NIRF) imaging at different stages of the disease -5, 7 and 10 days of Dextran Sulfate Sodium (DSS) administration.Then, the efficacy of DEX-SPNs is tested in vitro over macrophages and in vivo by monitoring the animal weight, food and water intake; expression of inflammatory cytokines (TNF-α, IL-1β, IL-6); intestinal density of macrophages; rectal bleeding and histological scoring.150 nm DEX-SPNs are shown to deposit within the hyper-permeable inflamed intestine in a disease severity-dependent fashion.DEX-SPNs exposed to LPS-stimulated RAW 264.7 cells reduce the expression of inflammatory cytokines as rapidly as free DEX.In DSS-administered mice, DEX-SPNs treatments improve weight loss, reduce the macrophage infiltration, expression of inflammatory cytokines, rectal bleeding and histological scoring, as compared to free DEX.Moreover, DEX-SPNs exert a strong systemic anti-inflammatory effect and facilitate animal recovery.This work confirms the benefits of using sufficiently small nanoconstructs for targeting inflamed, hyper-permeable tissues and efficiently delivering high doses of corticosteroids for the treatment of intestinal and systemic inflammation.
FRI0715 Being a woman and having knee osteoarthritis increases the likelihood of comorbidities
Authors: M Herrero Barbero, S Gimenez, J Vergara, E I Lladό Viles, H Martinez, G Rodríguez Roca, L Sánchez, JA Muñoz Díaz, JF Frias, A Castaño, JJ Díaz Jiménez, Ά de Cossío Rodríguez, R Belenguer, JL Llisterri, J Vergés Milano
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Osteoarthritis (OA) is the most prevalent joint disease and the leading cause of disability from 60 years onwards. In fact, 14,8% of the Spanish population has OA. <h3>Objectives</h3> This study aimed to determine if there is a differential profile and greater comorbidity in women affected by symptomatic knee OA compared to a control group without OA. <h3>Methods</h3> The EMARTRO study was designed as an observational, multicenter, transversal study to compare probability of suffering a comorbidities based on presence of symptomatic knee OA visited by GPs. Sociodemographic, anthropometric, clinical parameters and clinical variables of interest were recorded. The probability of suffering comorbidities in each study group was estimated using the Odds Ratio estimation with conditioned logistic regression models. The HAD scale, the Goldberg health questionnaire were administered to patients and the concomitant medication was also registered. The comparison between groups was done using t-Student, Chi-square and Mann-Whitney. <h3>Results</h3> A total of 897 women were included with a mean (SD) age of 67.4 (6.8) years. Osteoarthritic women were obese and had a higher BMI compared with control group, 31.2 (5.5) vs 27.5 (4.3) (p&lt;0.0001), respectively. Regarding blood pressure, no differences were found in the systolic BP (p=0.0646) but in the diastolic, women with OA also had higher values, 77.9 (9.1) vs 75.8 (8.9) mmHg (p=0.0005). In general terms, the presence of OA doubled the probability of having concomitant conditions with respect to controls [OR=2,220 (95% CI: 1,449–3,400) p=0,0002]. Likewise, women with syntomatic knee OA were more likely to have hypertension [OR=1.697 (95% CI 1.299–2.217), p=0.0001], venous peripheral vascular disease [OR=2.148 (95% CI 1.547–2.984), p&lt;0.0001] and gastroesophageal reflux (OR=1.890 (95% CI 1.297–2.754), p=0.0009). Regarding the mental health of the patients, according to the Goldberg scale, 41% of the patients with OA elicited psychopathology vs 17.8% in controls, p&lt;0.0001. As for the HAD scale, there were more cases of anxiety (p&lt;0.0001) and depression in the OA women (p&lt;0.0001). The greater burden of physical and mental comorbidity in the OA patients was accompanied by a higher consumption of concomitant medications (p&lt;0.0001). <h3>Conclusions</h3> The results of the present study indicate that in patients with knee OA, being female is a risk factor for the development of concomitant pathologies. Also, the increased likelihood of suffering from hypertension, venous peripheral vascular disease and gastroesophageal reflux should determine chronic medications for the treatment of osteoarthritis. <h3>Disclosure of Interest</h3> None declared
SP0120 Predicting the risk of falls and promoting balance in older adults
Authors: D Rose
Journal: Annals of the Rheumatic Diseases (2017)

Falls are the leading cause of injury and death due to injury among the older adult population in the United States. Of those who fall, 24% will sustain serious injuries and 6% will experience fractures. In addition to injury, older adults who fall may experience decreased functional ability, loss of independence, a poorer quality of life, or premature mortality. At a global level, these statistics are similar among developed countries. It is important to first identify the intrinsic and extrinsic risk factors that contribute to falls and then intervene appropriately once the level of fall risk has been identified. It is important to understand that there is no one size suits all fall risk reduction program and that the type of program will vary as a function of the level of risk. Core components of successful fall risk reduction programs include exercise, environmental modifications, and behavior change techniques aimed at fostering long-term adherence to engaging in fall risk reducing behaviors. The purpose of this presentation will be to describe appropriate methods for identifying fall risk, and intervention strategies that have been shown to significantly reduce fall risk and/or fall incidence rates across the continuum of fall risk. <h3>Disclosure of Interest</h3> None declared
SP0099 Why capillaroscopy can predict disease severity and prognosis
Authors: M Cutolo
Journal: Annals of the Rheumatic Diseases (2017)

Nailfold capillaroscopy (NVC) is today considered to be safe biomarker in order to make an early diagnosis of slected Connective Tissue Diseases (CTDs) in presence of Raynaud9 phenomenon, and to measure progressive microvascular and tissues damage including response to long term treatment, Systemic sclerosis is the only CTD to date in which prognostic indices have been described to predict clinical complications. Predictions have been made based on baseline capillaroscopic images and based on sequential capillaroscopic follow-up. Baseline qualitative-assessed scleroderma patterns have been described to be linked with future organ involvement in any of the nine organ systems affected by SSc according to the disease severity scale of Medsger (general, peripheral vascular, skin, joint, muscle, gastrointestinal tract, lung, heart and kidney) (1). Additionally, baseline capillaroscopic evaluations have been linked to future development of digital trophic lesions in SSc. A simple scoring system has been used recently in the largest pan-European study evaluating the role of capillaroscopy in predicting digital ulcers in SSc (2). More specifically, in this study, simply the number of capillaries per linear mm had been evaluated. Besides counting the number of capillaries/capillary alterations, dimensions can also be measured. The latter has also been used in prediction of patients with RP whether, because of SSc, there will be a possibility for them to develop a secondary RP. Similarly, it has recently been attested that if the average capillary diameter (average of the largest apical, efferent and afferent limb in 16 fields, more specifically 2 fields per finger, fingers 2–5 from each hand) is less than 30 μm in a group of patients with RP but without scleroderma characteristic findings on nailfold videocapillaroscopy (NVC), the patient has a low chance of developing SSc, while if &gt;30 μm, then the patient has 50% chance to develop SSc (3). Concerning the ability of capillaroscopy to measure response to treatment, there are yet no prospective randomized, double-blind, placebo-controlled trials, evaluating the ability of capillaroscopy to monitor response to therapy concerning RP-related outcome measures. It is noteworthy and promising that in small studies showing response of immunosuppressive/vasomodulating treatment on disease severity, outcome measures are available (4–6). <h3>References</h3> V. Smith et al. J Rheumatol 40,2013,52–7. M. Cutolo et al. Arthritis Rheumatol 68,2016,2527–39. A. Trombetta et al. J Rheumatol 43,2016, 599–606. I. Miniati et al. Ann Rheum Dis 68, 2009;94–8. V. Smith et al. J Rheumatol 43, 2016,995–6 6. A. Trombetta, C et al. J Rheumatol. 2016;43:2033–41. <h3>Disclosure of Interest</h3> None declared
Identification of CHD4 As a Potential Therapeutic Target of Acute Myeloid Leukemia
Authors: Yaser Heshmati, Gözde Turköz, Aditya Harisankar, Sten Linnarsson, Marios Dimitriou, Indranil Sinha, Sören Lehmann, Hong Qian, Julian Walfridsson
Journal: Blood (2016)
AB0328 Rheumatoid arthritis and fear of falling: the influence of disease activity
Authors: J Bahha, B Amine, M Erraoui, Y Boujenane, S Fellous, I El Binoune, R Bahiri
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> The objective of this study was to evaluate fear of falling in patients with established RA and its relation to disease activity. <h3>Methods</h3> A cross-sectional study that included patients with rheumatoid arthritis. We collected the following data: age, sex, duration of disease, body mass index (BMI). Fear of falling was evaluated by the Falls Efficacy Scale-International score (FES-I) which consists of 16 different activities, scored using a four point scale (1=not at all concerned, 2=somewhat concerned, 3=fairly concerned and 4=very concerned). The summed scores for the 16 activities for each participant were calculated. Scores of ≥23 indicated a significant fear of falling. Disease activity was measured with swollen and tender joint count (SJC28, TJC28), pain on a visual analogue scale (VAS pain), patient and evaluator global assessment of disease activity (PGA, EGA), HAQ disability index (HAQ-DI), 28-joint DAS (DAS-28) and the clinical and simple disease activity indexes (CDAI, SDAI). Correlations were used to assess the relationship between fear of falling and disease activity. <h3>Results</h3> Thirty-three patients were included. The mean age was 49.3±10.5 years with female predominance (n=29 (87.9%)). The mean disease duration was 9.9±7.5 years. The mean FES-I score was 37.4±15.1 and 69.7% (n=23) of patients had significant fear of falling. The mean VAS pain was 5.3±2.5, the PGA was 6.2±2.1 and the EGA was 5.7±1.7. The mean HAQ-DI was 1.3±0.8. The mean DAS28 score was 5.5±1.3. The mean CDAI was 29.9±13.6 and the SDAI was 31.6±13.7. FES-I was significantly correlated with TJC28 (r =0.52, p=0.02), PGA (r=0,56, p=0,01), EGA (r=0,39, p=0,025), HAQ-DI (r =0.70, p=0001), DAS28 (r =0, 38, p=0.029), CDAI (r =0.48, p=0.005) and SDAI (r =0.52, p=0.002). <h3>Conclusions</h3> This study suggests that fear of falling is frequent in patients with rheumatoid arthritis and demonstrated that fear of falling is significantly correlated with disease activity. <h3>Disclosure of Interest</h3> None declared
THU0107 Association of global DNA methylation with MTX response and adverse events in early rheumatoid arthritis
Authors: H Gosselt, MD Rotte, M Chisholm, M Hazes, RD Jonge, S Heil
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Methotrexate (MTX) is a first-line therapy in early Rheumatoid Arthritis (RA). However, ∼30% of treated patients do not respond to the medicine or need to abrogate treatment because of severe adverse events. Since MTX interferes with the folate cycle and thereby influences the methylation cycle, we hypothesize that methylation status at start therapy is associated with response and adverse events after three months of MTX treatment enabling personalized medicine. <h3>Objectives</h3> Examine global methylation status of early Rheumatoid Arhtritis patients before and after 3 months of MTX use between responders and non-responders and patients that do or do not experience adverse events. <h3>Methods</h3> To assess global methylation status, DNA was isolated at baseline from whole blood of 120 patients from the Treatment in the Rotterdam Early Arthritis Cohort (tREACH), a multicenter, stratified single-blind clinical trial of patients with early RA. Methylation status of 7 CpG sites within Long-interspersed nuclear elements (LINE-1) were analyzed and quantified by Matrix Assisted Laser Desorption Ionization time of flight Mass Spectrometry (MALDI-TOF MS). Results were compared between MTX responders and non-responders based on a low disease activity (DAS28 &lt;3.2) at three months of treatment and patients experiencing ≤2 or ≥3 adverse events. Gastrointestinal adverse events were assessed separately. <h3>Results</h3> No statistical differences in the mean of 7 LINE-1 CpGs were observed between responders and non-responders, nor in patients experiencing ≤2 or ≥3 adverse events. However, methylation status of specific CpG sites within LINE-1 did show significant changes. Baseline CpG_2 methylation levels were positively correlated with the DAS28 score at t3 (p=0.018) and baseline methylation levels in CpG_5 and CpG_8.9 were significantly higher in patients experiencing ≥3 adverse events (p=0.018 and p=0.034, respectively). Besides, CpG_5 methylation levels were particularly increased in patients experiencing gastrointestinal adverse events (p=0.038). <h3>Conclusions</h3> Global methylation status is associated with non-response and adverse events to MTX in early RA patients and can therefore be implemented in future prediction models. <h3>Disclosure of Interest</h3> None declared